Public voting for the Open Science Prize closes this Friday, January 6, and OpenTrialsFDA, led by OHSU Associate Professor, Dr. Erick Turner, is one of the finalists. This week the OHSU community is rallying to get OpenTrialsFDA shortlisted to receive the $230,000 prize. The Open Science Prize is a partnership between the NIH, the Wellcome Trust, and the Howard Hughes Medical Institute to “unleash the power of open content and data to advance biomedical research” and its application to improve health. OpenTrialsFDA is one of six international teams that have been working since May 2016 to build prototypes that realize this vision.
While the boundaries of Open Science are debatable, in practice its advocates aim to make scientific research freely accessible and maximally interoperable to drive discovery, economic growth and human health. Increasingly, the most vocal advocates for open science practices are scientific thought leaders, funders, and policy makers — stakeholders that truly influence how we work. Indeed, in early December, the NIH Office of the Associate Director for Data Science hosted the Open Data Science Symposium, a public event exploring how Open Data and Open Science are transforming biomedical research. Nearly 1,200 people attended and listened to both the current and a former NIH director passionately and practically describe the importance of data sharing for accelerating research.
Dialogue on Open Science between NIH Director Dr. Francis Collins and Former NIH Director Dr. Harold Varmus, moderated by Chris Wiggins, Chief Data Scientist for The New York Times. Image: https://datascience.nih.gov/blog/OpenDataScienceSymposium2016
OpenTrialsFDA is designed to make clinical trial data from FDA reviews more discoverable, searchable, and actionable. It addresses important problems and has broad clinical relevance. Unlike the published literature, which often provides a biased picture of drug efficacy and safety, FDA reviews contain comprehensive methodological, protocol, and outcomes information. While the FDA makes this data available via a public database, the documents are difficult to search and link to other content; therefore, it is underutilized by researchers, clinicians, and the public. OpenTrialsFDA fixes this problem, and combined with its parent project, OpenTrials, provides a linked foundation of publically accessible clinical trial data to inform clinical decision making and new research.
OpenTrialsFDA needs your votes to win the Open Science Prize, which will allow Dr. Turner and his team to fully develop this important tool. Only 3 teams will be shortlisted and considered by the expert panel of advisors for the $230,000. You can learn more about OpenTrialsFDA via this short video and explore the prototype.
Vote here and spread the word by Friday, January 6 at 11:59 PM PST to make OpenTrialsFDA and OHSU an Open Science Prize winner!
Additionally, if you’re looking for a deep dive on the Open Science Prize and reflections on how to evaluate the finalists, read this post from OHSU Associate Professor, Dr. Melissa Haendel.